Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Biological Assembly Evidence: gel filtration

Biological Assembly 2  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors.

Biological Assembly 3  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 3 assigned by authors.

Biological Assembly 4  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 4 assigned by authors.

Macromolecule Content

• Total Structure Weight: 138.08 kDa 
• Atom Count: 10331 
• Modelled Residue Count: 1166 
• Deposited Residue Count: 1212 
• Unique protein chains: 1

6MOM

Crystal structure of human Interleukin-1 receptor associated Kinase 4 (IRAK 4, CID 100300) in complex with compound NCC00371481 (BSI 107591)

• PDB DOI: 10.2210/pdb6MOM/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Trichoplusia ni
• Mutation(s): No 


• Deposited: 2018-10-04 Released: 2019-10-16 
• Deposition Author(s): Abendroth, J., Mayclin, S.J., Lorimer, D.D., Starczynowski, D., Hoyt, S., Tawa, G., Thomas, C.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.207 
• R-Value Work: 0.167 
• R-Value Observed: 0.168 

Literature

Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Melgar, K., Walker, M.M., Jones, L.M., Bolanos, L.C., Hueneman, K., Wunderlich, M., Jiang, J.K., Wilson, K.M., Zhang, X., Sutter, P., Wang, A., Xu, X., Choi, K., Tawa, G., Lorimer, D., Abendroth, J., O'Brien, E., Hoyt, S.B., Berman, E., Famulare, C.A., Mulloy, J.C., Levine, R.L., Perentesis, J.P., Thomas, C.J., Starczynowski, D.T.

(2019) Sci Transl Med 11

• PubMed: 31484791 
• DOI: 10.1126/scitranslmed.aaw8828
• Primary Citation of Related Structures:  
  6MOM


• PubMed Abstract: 
  

Targeted inhibitors to oncogenic kinases demonstrate encouraging clinical responses early in the treatment course; however, most patients will relapse because of target-dependent mechanisms that mitigate enzyme-inhibitor binding or through target-independent mechanisms, such as alternate activation of survival and proliferation pathways, known as adaptive resistance. Here, we describe mechanisms of adaptive resistance in FMS-like receptor tyrosine kinase (FLT3)-mutant acute myeloid leukemia (AML) by examining integrative in-cell kinase and gene regulatory network responses after oncogenic signaling blockade by FLT3 inhibitors (FLT3i). We identified activation of innate immune stress response pathways after treatment of FLT3-mutant AML cells with FLT3i and showed that innate immune pathway activation via the interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) complex contributes to adaptive resistance in FLT3-mutant AML cells. To overcome this adaptive resistance mechanism, we developed a small molecule that simultaneously inhibits FLT3 and IRAK1/4 kinases. The multikinase FLT3-IRAK1/4 inhibitor eliminated adaptively resistant FLT3-mutant AML cells in vitro and in vivo and displayed superior efficacy as compared to current targeted FLT3 therapies. These findings uncover a polypharmacologic strategy for overcoming adaptive resistance to therapy in AML by targeting immune stress response pathways.

---

Organizational Affiliation: 

Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Interleukin-1 receptor-associated kinase 4	A, B, C, D	303	Homo sapiens	Mutation(s): 0  Gene Names: IRAK4 EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NWZ3 (Homo sapiens) Explore Q9NWZ3  Go to UniProtKB:  Q9NWZ3
PHAROS:  Q9NWZ3 GTEx:  ENSG00000198001

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
JX4 (Subject of Investigation/LOI)	E [auth A], F [auth B], H [auth C], I [auth D]	6-[7-methoxy-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-N-[(3R)-pyrrolidin-3-yl]pyridin-2-amine C21 H23 N7 O IALDYVNFZAPNJV-OAHLLOKOSA-N
EDO	G [auth B], J [auth D]	1,2-ETHANEDIOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N

Modified Residues  2 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
SEP	A, B, C, D	L-PEPTIDE LINKING	C3 H8 N O6 P		SER
TPO	A, B, C, D	L-PEPTIDE LINKING	C4 H10 N O6 P		THR

Binding Affinity Annotations
ID	Source	Binding Affinity
JX4	Binding MOAD:  6MOM	IC50: 0.8 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.10 Å
• R-Value Free: 0.207 
• R-Value Work: 0.167 
• R-Value Observed: 0.168 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 138.29	α = 90
b = 141.91	β = 126.22
c = 87.89	γ = 90

Software Package:

Software Name	Purpose
XDS	data reduction
XSCALE	data scaling
PHENIX	refinement
PDB_EXTRACT	data extraction
MoRDa	phasing
Coot	model building

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2018-10-04 
• Released Date: 2019-10-16 
Deposition Author(s): Abendroth, J., Mayclin, S.J., Lorimer, D.D., Starczynowski, D., Hoyt, S., Tawa, G., Thomas, C.

Revision History  

• Version 1.0: 2019-10-16
  Type: Initial release